News VACCINEXPAR

Equities

VCNX

US9186403013

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-22 pm EDT			5-day change	1st Jan Change
4.94 ^USD	+1.65%		-1.79%	-46.92%

Apr. 12	Vaccinex, Inc. announced that it has received $1.75 million in funding	CI
Apr. 02	Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vaccinex, Inc. announced that it has received $1.75 million in funding	Apr. 11	CI
Vaccinex Reports 2023 Financial Results and Provides Corporate Update	Apr. 02	AQ
Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
Vaccinex, Inc. announced that it expects to receive $1.75 million in funding	Mar. 28	CI
Vaccinex, Inc. announced that it has received $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	Mar. 27	CI
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	Mar. 27	AQ
Vaccinex, Inc. announced that it expects to receive $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	Mar. 26	CI
Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding	Mar. 26	CI
Vaccinex, Inc. Announces Chief Financial Officer Changes, Effective March 14, 2024	Mar. 04	CI
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024	Mar. 04	CI
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	Feb. 21	MT
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform	Feb. 21	MT
Vaccinex, Inc. Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology	Feb. 21	CI
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology	Feb. 21	AQ
Vaccinex, Inc. Announces Reverse Stock Split	Feb. 15	AQ
Vaccinex Announces Pricing of $3.7 Million PIPE Financing	Feb. 07	AQ
Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding	Feb. 06	CI
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule	Dec. 04	AQ
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 13	AQ
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News VACCINEXPAR

Equities

VCNX

US9186403013

Summary

Filters